Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2⁺HR⁺ breast cancer.

ABSTRACT: Recent evidences from clinical trials (NCT04486911) revealed that the combination of pyrotinib, letrozole, and dalpiciclib exerted optimistic therapeutic effect in treating HER2⁺HR⁺ breast cancer; however, the underlying molecular mechanism remained elusive. Through the drug sensitivity test, the drug combination efficacy of pyrotinib, tamoxifen, and dalpiciclib to BT474 cells was tested. The underlying molecular mechanisms were investigated using immunofluorescence, Western blot analysis, immunohistochemical staining, and cell cycle analysis. Potential risk factor that may indicate the responsiveness to drug treatment in HER2⁺/HR⁺ breast cancer was identified using RNA-sequence and evaluated using immunohistochemical staining and in vivo drug su

SUBMITTER: Bu J 

PROVIDER: S-EPMC9822241 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature